Novartis AG ADR (NVS)vsSo-Young International Inc (SY)
NVS
Novartis AG ADR
$145.23
-0.55%
HEALTHCARE · Cap: $277.42B
SY
So-Young International Inc
$2.95
-2.96%
HEALTHCARE · Cap: $297.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3614% more annual revenue ($56.58B vs $1.52B). NVS leads profitability with a 23.9% profit margin vs -15.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SY
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$145.23
$35.11 premium
Intrinsic value data unavailable for SY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.8% year-over-year
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : SY
The primary concerns for SY are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while SY is a growth play — different risk/reward profiles.
SY carries more volatility with a beta of 2.13 — expect wider price swings.
SY is growing revenue faster at 24.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?